This document outlines the procedure for Orthoptists performing intravitreal injections (IVT) of Anti-VEGF or steroid implants. This will include Anti-VEGFs such as:
- Ranibizumab (Lucentis)
- Aflibercept (Eylea)
- Bevacizumab (Avastin)
- Brolucizumab (Beovu)
- Or steroid intravitreal implants such as Dexamethasone (Ozurdex)
Orthoptists must comply with these standards to be insured for professional practice for Age-Related Macular Degeneration (AMD), Diabetic Macular Oedema (DMO), retinal vein
occlusion (RVO), Uveitis, and other macular disorders.
